Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mucochloric Acid SCHEMBL1010785 | 0.72 | — | — | |
| SCHEMBL16245792 | 0.68 | — | — | |
| SCHEMBL2143796 | 0.65 | ALDH1A1 (1.00) | ALDH1A1HIF1AHSD17B10 | |
| SCHEMBL4302916 | 0.64 | ALDH1A1 (0.68) | ALDH1A1HIF1AHSD17B10 | |
| SCHEMBL3908860 | 0.63 | ALDH1A1 (0.71) | ALDH1A1HIF1AHSD17B10 | |
| SCHEMBL20016461 | 0.61 | APP (0.33) | ALDH1A1HIF1AHSD17B10 | |
| SCHEMBL11832803 | 0.61 | MAPT (0.34) | ALDH1A1HIF1AHSD17B10 | |
| Mucochloric Acid SCHEMBL31295685 | 0.59 | ALDH1A1 (0.42) | ALDH1A1HIF1AHSD17B10 | |
| Mucochloric Acid SCHEMBL31295686 | 0.59 | ALDH1A1 (0.42) | ALDH1A1HIF1AHSD17B10 | |
| SCHEMBL11276380 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136987-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4491184-A2 | CHANNEL MODULATORS | Auckland Uniservices Limited (NZ) | 2025-01-15 | — | — | EP | disclosed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | disclosed |
| US-20230174980-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11401516-B2 | Channel modulators | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-08-02 | — | — | US | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210115445-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20200263175-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200239889-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10465188-B2 | Channel modulators | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-11-05 | — | — | US | disclosed |
| WO-2009097077-A2 | WOUND HEALING COMPOSITIONS AND TREATMENTS | CODA THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009085274-A2 | USE OF ANTI-CONNEXIN POLYNUCLEOTIDES AND PEPTIDES FOR THE TREATMENT OFABNORMAL OR EXCESSIVE SCARS | CODA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085268-A2 | USE OF ANTI-CONNEXIN PEPTIDES, ALONE OR IN COMBINATION WITH ANTI-CONNEXIN POLYNUCLEOTIDES, FOR THE TREATMENT OF SURGICAL ADHESIONS | CODA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085275-A2 | USE OF ANTI-CONNEXIN POLYPEPTIDE AGENT IN COMBINATION WITH ANTI-CONNEXIN POLYNUCLEOTIDE AGENT FOR THE TREATMENT OF FIBROTIC CONDITIONS | CODA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085271-A2 | USE OF ANTI-CONNEXIN PEPTIDES, ALONE OR IN COMBINATION WITH ANTI-CONNEXIN POLYNUCLEOTIDES, FOR THE TREATMENT OF ORTHOPEDIC CONDITIONS | CODA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085272-A2 | IMPROVED MEDICAL DEVICES | CODA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009075881-A2 | IMPAIRED WOUND HEALING COMPOSITIONS AND TREATMENTS | CODA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075882-A2 | IMPAIRED WOUND HEALING COMPOSITIONS AND TREATMENTS | CODA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008060622-A9 | IMPROVED METHODS AND COMPOSITIONS FOR WOUND HEALING | CODA THERAPEUTICS INC (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008060622-A2 | IMPROVED METHODS AND COMPOSITIONS FOR WOUND HEALING | CODA THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174980-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | ALDH1A1 3694/4885HIF1A 1117/4885HSD17B10 4389/4885 |
| US-20200263175-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | ALDH1A1 3694/4885HIF1A 1117/4885HSD17B10 4389/4885 |
| US-10465188-B2 | Channel modulators | GJB2, GJA1, P2RX2 | ALDH1A1 3694/4885HIF1A 1117/4885HSD17B10 4389/4885 |
| US-11401516-B2 | Channel modulators | GJB2, GJA1, P2RX2 | ALDH1A1 3694/4885HIF1A 1117/4885HSD17B10 4389/4885 |
| US-20200239889-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | ALDH1A1 3694/4885HIF1A 1117/4885HSD17B10 4389/4885 |
| US-20250136987-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | ALDH1A1 3694/4885HIF1A 1117/4885HSD17B10 4389/4885 |
| US-20210115445-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | ALDH1A1 3694/4885HIF1A 1117/4885HSD17B10 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.